Delving into the Latest Updates on Debio-1142 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization

Debiopharm International SA

Active Organization-

Inactive Organization

Aurigene Oncology Ltd.

Debiopharm International SA

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC33H32F3N7O2

InChIKeyWVGSOXRZIVSEQO-UHFFFAOYSA-N

CAS Registry1332328-01-4

Janus kinase 2 plays a critical role in JAK/STAT signaling pathways, and has a central role in cell cycle.JAK2 have emerged as a novel therapeutic target of myeloproliferative disorders, autoimmune diseases, essential thrombocytosis, and small mol. inhibition of JAK2 activity developed into an impressive drug target.For a series of JAK2 inhibitors pharmacophore model and atom-based 3D-QSAR models have been developed, to identify the essential structural features required for these JAK2 inhibitors using the PHASE module of Schrodinger.A five featured pharmacophore hypothesis with three hydrogen bond acceptors, one hydrogen bond donor and one aromatic ring provided a best atom-based 3D-QSAR model.The developed 3D-QSAR model have good statistical predictive values as R2 = 9659, Q2 = 0.5679 and effective Pearson R = 0.9405.The results illustrate the structural information of substituted aromatic bicyclic compounds containing pyrimidine and pyridine rings, which might be supportive for further rational design of novel potent Janus kinase 2 inhibitors.

100 Deals associated with Debio-1142

Login to view more data